Cocaine-Induced Microvascular Dysfunction and its Reversal by Administration of Intracoronary Calcium-Channel Blocker

Bhalaghuru Chokkalingam Mani, David L Fischman, Michael P Savage1

  • 1Cardiac Catheterization Laboratory, Thomas Jefferson University Hospital. Gibbon Bldg., Ste 6210, 111 S. 11th Street, Philadelphia, PA 19107 USA. michael.savage@jefferson.edu.

Insights

This case study highlights a novel treatment for cocaine-induced chest pain. An intracoronary calcium-channel blocker effectively treated microvascular spasm in a patient unresponsive to nitroglycerin.

Area of Science:

  • Cardiology
  • Pharmacology
  • Toxicology

Background:

  • Cocaine use is associated with cardiovascular complications, including myocardial infarction and vasospasm.
  • Chest pain is a common presentation in patients with cocaine-induced cardiovascular events.
  • Standard treatments like nitroglycerin may be ineffective in severe cases.

Observation:

  • A 47-year-old male smoker with recent cocaine use presented with persistent chest pain.
  • The patient's chest pain was refractory to both sublingual and intravenous nitroglycerin.
  • This refractory presentation suggested a microvascular etiology, possibly related to cocaine's sympathomimetic effects.

Findings:

  • The study reports the first successful use of an intracoronary calcium-channel blocker to manage cocaine-induced microvascular spasm.
  • Administration of the calcium-channel blocker resulted in rapid amelioration of chest pain and likely restored coronary blood flow.
  • This intervention targeted the specific mechanism of cocaine-induced coronary microvascular dysfunction.

Implications:

  • Intracoronary calcium-channel blockers represent a potential therapeutic option for refractory cocaine-induced coronary vasospasm.
  • This approach may be particularly useful in patients who do not respond to conventional therapies.
  • Further research is warranted to establish the safety and efficacy of this treatment strategy in a larger cohort.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
376
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
868